Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial
Haruhiro Saito(Kanagawa Cancer Center), Makoto Maemondo(Miyagi Prefectural Hospital Organization), Akihiko Gemma(Nippon Medical School), Gyo Asai(Aichi Cancer Center), Kozo Yoshimori(Japan Anti Tuberculosis Association), Kunihiko Kobayashi(Saitama International Medical Center), Shunichiro Iwasawa(Chiba University), Ou Yamaguchi(Saitama International Medical Center), Futoshi Kurimoto(Saitama Cancer Center), Koichi Azuma(Kyushu University Hospital), Yukari Tsubata(Shimane University), Ichiro Nakachi(Saiseikai Utsunomiya hospital), Tatsuro Fukuhara(Miyagi Prefectural Hospital Organization), Hiromi Nagashima(Iwate Medical University), Naoki Furuya(St. Marianna University School of Medicine), Yoshio Tsunezuka(Ishikawa Prefectural Central Hospital), Shunichi Sugawara(Sendai Kousei Hospital), Satoshi Morita(Kyoto University), Masaki Miyazaki(Suita Municipal Hospital), Yuka Fujita, Morihito Okada(Hiroshima University), Toshihiro Nukiwa(Tohoku University), Satoshi Watanabe(Niigata University Medical and Dental Hospital), Kana Watanabe(Miyagi Prefectural Hospital Organization), Koichi Hagiwara(Jichi Medical University)
Cited by 636
Related Papers
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
A cross-population atlas of genetic associations for 220 human phenotypes
|Nature Genetics|2021|2.4k
Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (JCOG0802/WJOG4607L): a multicentre, open-label, phase 3, randomised, controlled, non-inferiority trial
|The Lancet|2022|1.6k
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
|The Lancet|2021|1.5k
Nrf2 Redirects Glucose and Glutamine into Anabolic Pathways in Metabolic Reprogramming
|Cancer Cell|2012|1.4k